Close Menu

NEW YORK (360Dx) – Sciex said today it has formed a joint venture between its diagnostics division and Chinese firm Zhejiang Dian Diagnostics around mass spec-based testing.

The venture will be based in Hangzhou, China and will develop, register, manufacture, and commercialize Class I, II and III in vitro diagnostic reagents for the SCIEX Triple Quad™ 4500MD LC-MS/MS system, Sciex said. The 4500MS received Chinese Food and Drug Administration approval earlier this year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.